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Abstract 
BACKGROUND: Direct oral anticoagulant-rivaroxaban may provide a simple, fixed-dose therapy for the 
management of hospital-acquired, acute venous thromboembolism (VTE) and for extended treatment, its use 
could skip lab observation and/or parenteral treatment. 
AIM: Compare the efficacy and safety (EAS) of RIV vs. standard therapy (SDTD) in a cohort of Vietnamese 
patients diagnosed with symptomatic, acute VTE. 
METHODS: An open-label, case-control, prospective study was conducted to check the efficacy and safety (EAS) 
of oral rivaroxaban (RIV) alone (15 mg 2 times/day for 3 weeks, then 20 mg 1 time/day) in a comparison to the 
standard therapy (STDT) (enoxaparin 1.0 mg/kg 2 times/day combining with vitamin K antagonist). Patients were 
treated for 6 months and followed-up for suspect reoccurring VTE and bleeding. 
RESULTS: A total 187 patients were enrolled into study. 83 were provided rivaroxaban and 104 received 
enoxaparin overlapping with vitamin K antagonist (VKAs). Recurrent VTE occurred in 3 (3.6%) rivaroxaban-
received patients compared with 5 (4.8%) standard-treatment received patients (OR: 0.74, 95% CI, 0.17 to 3.20, p 
> 0.05). Major bleeding events were found in 1 (1,8%) and 4 (3.9%) cases in the RIV treated and STDT cohort, 
respectively (OR: 0.30, 95% CI, 0.03 to 2.76, p > 0.05). 
CONCLUSION: The finding of this study in Vietnamese patients with acute VTE presented comparable EAS 
profile with RIV versus STDT, consistent with those found in global population. 
 
 
Introduction 
 
Venous thromboembolism (VTE), (for 
example deep venous thromboembolism (DVT) or 
pulmonary embolism (PE)) is a major issue which 
cause annual prevalence of about 100 – 200 cases 
per 100,000 individual in the Western countries [1], 
[2]. In Asia, the prevalence of VTE has increased over 
recent years, however, it is often knownto be lower 
than that in Caucasian population [3], [4]. 
Anticoagulant therapy effectively minimize the rate of 
recurrent VTE from 25% to 3% approximately within 
the period from 6 to 12 months, but the risk of VTE 
reoccurrence was stable at around 5-10% after one 
year of treatment [5]. 
Standard guidelines on antithrombotic therapy 
for VTE commonly suggest the application of 
enoxaparin (low molecular weight heparins) plus 
vitamin K antagonists (VKAs). However, it still has 
some limitations. Enoxaparin requires uncomfortable 
subcutaneous injection on a daily or twice daily basis 
while treatment with VKAs demands lab observation 
and cautious dosage modification and may be 
complicated by interacting with food and concomitant 
drug. After one year, the likelihood of occuring major 
bleeding event with regard to the use of VKAs is 
approximately 1 to 2% annually [6]. As a result, the 
debate on balancing the advantages and the 
disadvantages of continuous therapy were still 
controversial, regardless of the high likelihood of VTE 
reoccurrence in a long term. An absolute method to 
solve several of these concerns might be introduction 
of new oral anticoagulant that skip the requirement for 
parenteral medication and routine lab observation but 
shows effectiveness as a single factor for acute and 
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continued treatment of symptomatic VTE. 
Rivaroxaban (RIV), a new oral anticoagulant, 
acts through activedirect inhibition of activated Factor 
Xa and shows a quick onset of peak anticoagulant 
effect (within 2-4 hours after dosing) and has 
calculable pharmacodynamic and pharmacokinetic 
properties, which restrain the requirement for daily 
observation of anticoagulation, has a low propensity 
for interacting with other drugs and does not need 
dietary restrictation [7]. The evaluation of RIV was 
implemented in global clinical trial in acute 
symptomatic VTE patients, and showed a comparable 
efficacy as enoxaparin plus VKA with reduced 
incidence of major bleeding [8], [9]. 
Although there are a number of published 
studies on using RIV for the intervention of 
thrombolysis conditions in the literature, this therapy is 
not well documented among Asian population. 
Therefore, we aimed to compare the efficacy and 
safety (EAS) of RIV vs. standard therapy (SDTD) in a 
cohort of Vietnamese patients diagnosed with 
symptomatic, acute VTE. 
 
 
Methods 
 
Study design 
This was a case-control, prospective study 
designed to evaluate the EAS of RIV in comparison 
with SDTD (enoxaparin overlapping with VKAs) in 
treating acute hospital-acquired VTE. The research 
was conducted at a teaching hospital (Cho Ray 
Hospital, Ho Chi Minh, Vietnam).  
 
Subject and sampling method 
Convenience sampling method is applied. All 
eligible patients are recommended to participate into 
study. 
Patients were enrolled in the study if they 
were ≥ 18-year olds and had been diagnosed as 
having acute, symptomatic DVT and/or PE. Patients 
were not included if therapeutic dosage of parenteral 
anticoagulant was given to patients for over 48 hours 
before randomization; or if thrombectomy had been 
performed, a vena cava filter required for the present 
occasion of thrombosis; or if patients were 
contraindicated for using anticoagulant. Other criteria 
for exclusion were: having significant hepatic disease; 
another designation for VKAs; cerebral haemorrhage; 
occurrence of bleeding or an increased likelihood of 
occurring bleeding,; renal failure with creatinine 
clearance levels < 30 mL/min; a systolic blood 
pressure (BP) of ≥ 180 mm Hg or diastolic BP of ≥ 
110 mm Hg; pregnancy or breast-feeding; or a life 
expectancy of ≤ 3 months. 
Treatment regimens 
Patients using rivaroxaban for VTE treatment 
were received 15 mg 2 times per day for the first 3 
weeks, then 20 mg were given 1 time per day 
continuously. Patients distributed to STDT received 
injection of enoxaparin with a dosage of 1.0 mg/kg of 
body weight two times per day, and vitamin K 
antagonists (warfarin or acenocoumarol), begun 
during 48 hours after selection. Anticoagulation with 
SDTD was stopped when the INR (international 
normalized ratio) was recorded as 2.0 or higher for 
two continuous days and after the patients had been 
given at a minimum of 5 day. The VKAs dosing was 
changed to sustain an INR of 2.0-3.0. Initially, the 
INRs were examined frequently, and when stabile, at 
least one time per month.  
 
Patients follow-up 
Follow-up for discharged patients was 
performed for intended treatment period (6 months) 
and evaluated at fixed intervals that were alike for 
both subgroups. Any signs and symptoms of VTE 
recurrence, bleeding and complications were elicited 
using a checklist among each outpatient visit. If any of 
signs and symptoms of these events happened, 
patients were guided to inform to physician. In case of 
clinically suspected VTE reoccurrence, objective 
testing was demanded. 
 
Outcomes 
The main outcome for this study was the 
prevalence of reoccurring VTE consisting of 
symptomatic DVT or PE. The criteria for detection of 
recurrent PE were as follow: a new intraluminal filling 
deficiency on pulmonary angiography or computed 
tomography scan, a new cutoff of a vessel of 2.5 mm 
or higher in caliber on pulmonary angiography, a new 
non-high probability perfusion defect related to DVT 
as determined by ultrasonography or venography. The 
criteria for identification of recurrent DVT were as 
follow: a new non-compressible venous segment or a 
significant enlargement (more than 4 mm) in the 
caliber of the blood clots during full compression in 
earlier uncommon sector on venous detected by 
ultrasound scan or on the appearance of a filling 
deficiency on venography. 
The outcome of safety was clinically relevant 
bleeding. Bleeding complications were classified as 
critical if it was clinically overt and required a 
transfusion of more than two units of packed red blood 
cells; was intracranial or retroperitoneal, appeared in 
another critical site and/or conduced to mortality. Non-
critical clinical bleeding was determined as observable 
bleeding that did not satisfy the criteria for major 
bleeding complication but was related to medical 
intervention, infrequent use of drug or abandonment 
of medication, unscheduled contact with doctor, or 
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impairment of daily activities. 
Mortality was identified as being because of 
PE, bleeding events or other causes happening during 
the time of continuous treatment. Pulmonary 
embolism was seen as the reason of decease if 
objective documentation of the disease were 
demonstrated, or if the reason of death was not 
discovered and PE could not be removed.  
 
Statistical analysis 
Desciptive statistics were conducted to 
analyze distribution of baseline characteristics in the 
two treatment arms. Qualitative variables were 
calculated as percentages and quantitative variables 
were calculated as average (± SD). Proportions and 
absolute differences and corresponding 95% 
confidence intervals (CI) were reported. Exact method 
was applied to calculate 95% CI. The results were 
recognized statistically significant if p < 0.05. 
 
 
Results 
 
From January 2017 to August 2018, a total of 
187 VTE patients were selected into the study. Of 
these, 83 were given RIV and 104 received 
enoxaparin overlapping with VKAs. Overall, 71 
patients receiving rivaroxaban (85%) had isolated 
DVT vs. 91 (87%) from standard treatment group; 
Moreover, 3.6% vs. 4.8% of patients had DVT and 
PE, and; 10.8% vs. 6.7% of patients had PE without 
DVT symptoms (Table 1). Limb swelling and leg pain 
were found as the most frequent signs in DVT patients 
while dyspnea and chest pain were mostly seen in PE 
patients. Their baseline and clinical characteristics 
appear in Table 1.  
Table 1: Baseline characteristics 
Characteristic RIV (n = 83) STDT (n = 104) p value 
Average age, (± SD) 57.08 ± 19.5 60.2 ± 16.4 0.24 
Male sex, n (%) 30 (36.1) 27 (25.2) 0.13 
Mean weight 55.8 ± 10.1 55.4 ± 9.0 0.84 
Concomitant disease, n (%) 33 (47.1%) 58 (59.8%) 0.12 
Concomitant therapy, n (%) 42 (50.6%) 49 (47.1%) 0.65 
Major bleeding occurring in previous month, n 
(%) 
1 (1.2%) 0 0.27 
Creatinine clearance, n (%)   0.63 
30 - < 50 mL/min 7 (8.4%) 13 (12.5%)  
50 - < 80 mL/min 28 (33.7%) 34 (32.7%)  
≥ 80 mL/min 44 (53.01%) 55 (52.9%)  
Cancer 5 (6%) 9 (8.4%) 0.74 
Recent surgery 2 (2.4%) 3 (2.8%) 0.99 
Immobilization (≥ 4 days) 8 (9.6%) 11 (10.6%) 0.41 
Estrogen therapy 1 (1.2%) 0 0.25 
Previous DVT or PE 3 (3.6%) 3 (2.9%) 0.60 
Any travel > 6 hours in the past 3 weeks  0 1 (0.096%) 0.37 
Puerperium 1 (1.2%) 2 (1.9%) 0.54 
Known thrombophilic condition 3 (3.6%) 4 (3.8%) 0.96 
Unprovoked VTE  62 71  
only DVT, n (%) 71 91  
DVT/PE 3 (3.6%) 5 (4.8%)  
Only PE 9 (10.8%) 7 (6.7%)  
 
 Among 83 patients treated with rivaroxaban, 
8.3% had been immobilized for the first 3 days of 
treatment. Meanwhile, there were 15 enoxaparin 
users who had been immobilized. 
Table 2: Characteristics related to anticoagulant treatment in 
both subgroups 
Characteristic RIV (n = 83) STDT (n = 104) p value 
Immobilization during the first 3 
days 
  0.45 
Complete, n (%) 1 (1.2%) 1 (0.96%)  
Relative, n (%) 7 (8.3%) 15 (14.4%)  
Mean time in INR range    
< 2.0 NA 15.3%  
2.0-3.0 NA 54.8%  
> 3.0 NA 27.9%  
Mean study treatment duration, 
days 
167.6 ± 15.8 169.2 ± 16.4 0.61 
Intended duration of treatment    
3 months 12 16  
6 months 70 88  
Note: P values were determined using Chi-square test. 
 
Besides, in both treatment arms, only one 
patient was immobilized at a complete degree. In the 
traditional treatment group, the INR being in 
therapeutic range (2.0-3.0) accounted for 54.8% of the 
time, INR values above 3.0 and below 2.0 occupied 
the corresponding percentage of time of 27.9% and 
15.3%, respectively (Table 2). None of participants 
was missing during follow-up 
Table 3: Clinical outcomes 
Treatment Outcomes RIV (n = 83) STDT (n = 104) Risk Ratio (95% CI) p 
Recurrent VTE, n (%) 3 (3.6%) 5 (4.8%) 0.74 (0.17-3.20) 0.69 
Type of VTE reoccurrence     
Fatal PE 0 0   
Nonfatal PE 1 1   
Reoccurring DVT plus PE 0 0   
Reoccurring DVT 2 3   
Death from any cause – n (%) 2 (2.4%) 4 (3.9%) 0.61 (0.11-3.43) 0.57 
PE 0 0   
Bleeding 0 0   
Cardiovascular 0 0   
Other 2 4   
Bleeding event, n (%)     
Major bleeding 1 (1.8%) 4 (3.8%) 0.30 (0.03-2.76) 0.26 
Clinically relevant non-major 
bleeding, n (%) 
9 (10.8%) 11 (10.6%) 1.02 (0.40-2.59) 0.97 
Note: P values were determined using Cox Proportional-Hazard Regression. 
 
The main efficacy outcome, recurrent VTE, 
was confirmed in 3 cases in the novel anticoagulant 
subgroup and in 4 cases in the STDT subgroup. 
There were 6 cases of death reported in the study, 2 
from treatment arm using rivaroxaban and 4 from 
group received enoxaparin plus VKA. However, the 
cause of death was not associated with VTE or 
bleeding complications, but other diseases such as 
stroke, respiratory insufficiency, and diabetes. 
Clinically relevant non-major bleeding events were 
observed in 9 cases in RIV subgroup and in 11 
patients in SDTD group. Major bleeding was detected 
in one rivaroxaban-received patient (1.8%) and in 4 
(3.8%) patients who were give enoxaparin overlapping 
with VKA (Table 3). 
 
 
Discussion 
 
Our analysis confirms that RIV shows 
comparable effectiveness to STDT in Vietnamese 
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patients also, with parallel safety for the intervention of 
symptomatic, acute VTE, and for the continuous 
treatment. The use of rivaroxaban presented a slight 
decrease in the frequency of reoccurring VTE in 
comparison with enoxaparin/VKA and presents 
acceptable likelihood of occurring bleeding event. 
Our study shows that the mean age of 
patients receiving rivaroxaban group was 56.5 ± 20.1 
years, slightly younger than those on standard therapy 
(61.2 ± 18.8 years). Mean age of in our study 
population was similar to that of EISTEIN study on 
Chinese patients: 58.6 ± 15.8 and vs. 59.0 ± 15.0 
years, respectively [10]. Male patients accounted for 
36.1% in RIV group and 25.2% in STDT group. The 
male proportions are lower compared to those in 
contemporary clinical studies [11], [12]. The risk 
factors that were most commonly observed in our 
patients were immobilization, cancer, history of 
thrombosis, and undergoing previous major surgery, 
which are consistent with population-based 
researches from Western countries [13], [14]. Overall, 
2.4% of patients given RIV and 2.8% of those 
receiving STDT, underwent major surgery before, 
which suggested that post-operative 
thromboprophylaxis failed in these surgical patients. 
The situation of low execution of thromboprophylaxis 
in surgical patients has been reported in previous 
studies [15], [16]. On the basis of these data, the 
enhancement of quality should highlight the 
importance of conducting more appropriate 
prophylaxis for patients at high risk. In addition, the 
VTE treatment in standard therapy group was done 
well suggesting that the proportion of time in which the 
INR was in the therapeutic range (2.0-3.0) was 54.8% 
and for INR above 3.0 was 27.9%. Our findings were 
consistent with the results which was showed in other 
contemporary studies on VTE treatment [17], [18]. 
We found that rivaroxaban is non-inferior to 
enoxaparin in relation with efficacy and safety. The 
prevalence of complications occurring during 6 
months of follow-up is comparable to the rate 
demonstrated by Wang and colleagues [10]. The 
frequency of reoccurring VTE in that analysis was 
3.2% in both STDT and RIV groups. In our study, 
reoccurring VTE was identified in 3.6% of patients 
who received RIV versus 4.8% of patients in the 
STDT group. Bleeding was the most prevalent 
complication in this study, occurring in both treatment 
arms during initial therapy. Interestingly, while the rate 
of non-critical bleeding complications in two groups 
was comparable to each other groups (10.8% and 
10.6%, respectively), the frequency of major bleeding 
was less common in rivaroxaban-given patients, 1.8% 
vs. 3.8% (OR: 0.26; 95% CI: 0.03-2.76). Our results 
seem to be slightly worse than those in the 
randomized clinical trials. For instance, the EINSTEIN 
study which compares the EAS of RIV vs. STDT 
(enoxaparin plus VKA) found the prevalence of major 
bleeding event to be 0.8% and 1.2% (OR: 0.65; 95% 
CI: 0.33-1.30; p = 0.21) in the RIV and STDT groups, 
respectively. The most likely explanation for this 
discrepancy could be differences in the exclusion 
criteria to recruit patients in both studies. Moreover, 
the frequency of non-critical bleeding events was 
identical between two arms (8.1% vs. 8.1%) [17]. 
Prins MH et al., implemented a comparison 
between oral rivaroxaban and enoxaparin combined 
with VKA on 8282 VTE treatment and suggested that 
the rate of mortality was 2.3% and 2.4% in the two 
subgroups. Of these, PE related mortality accounted 
for 0.4% of patients using rivaroxaban and 0.3% of 
those receiving enoxaparin combined with VKA while 
bleeding related to death appeared in corresponding 
proportion of 0.1% and 0.2% of number of patients [9]. 
In comparison, there were 6 patients who died during 
follow-up in our study, but the cause of death was 
non-related to VTE or bleeding. 
Several restrictions of our study had been 
noted. Firstly, since our study was designed as open-
label, there could be bias in outcomes assessment. 
However, endeavors were performed in order to 
restrict bias in investigation, consisting of the demand 
to apply diagnostic tests in detecting suspected 
reoccurring VTE, identical follow-up of all patients, 
and central adjudication of all outcome circumstances. 
Second, imbalance in patients’ characteristics may 
lead to more hospitalization or emergency department 
visit recorded in one treatment arm and more 
“recycled” VTE codes that will be carried forward 
instead of being associated with a “true” recurring 
VTE. In order to solve this, we restrained our endpoint 
of “recurrent VTE” only to hospital admissions, where 
“VTE” was the primary code. Third, the risk of 
bleeding is also probably modified by characteristics 
that alter during the course of therapy, such as the 
concurrent use of other drugs, or the existence of 
intercurrent disease. Finally, our study was conducted 
in only one hospital with small sample sizes, so it was 
not possible to assess the true efficacy of rivaroxaban 
on Vietnamese subjects, therefore, it was necessary 
to implement more clinical trials with larger sample 
sizes in many different centers. 
To conclude, the findings of this study confirm 
that the EAS of RIV are compared with those 
monitored in the larger clinical trials with parallel EAS 
and better bleeding profile compared to STDT 
(enoxaparin combined with VKA). The results suggest 
that rivaroxaban offers clinician with a new, better 
option in treatment of VTE for Vietnamese patients. 
 
 
Ethical Approval 
 
Research only aims to protect and improve 
the health of patients, not for any other purpose. This 
research was accepted by Ethical Review Board of 
Hanoi Medical University (Approval No. IRB 003121). 
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Informed consents were collected from 
participating patient(s) for their anonymized 
information to be reported in the study. 
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